YKYuji Kamikubo

Yuji Kamikubo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuji Kamikubo has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TREM2-LRP1 axis in Alzheimer's disease: pharmacological trade-offs of receptor shedding and functional restoration

    by Yuji Kamikubo

    The interplay between triggering receptor expressed on myeloid cells 2 (TREM2) and low-density lipoprotein receptor-related protein 1 (LRP1) is critical for amyloid-beta (Aβ) clearance in Alzheimer’s disease (AD). Current therapeutic strategies targeting this axis can be broadly divided into two pharmacological approaches: indirect induction via metabolic modulation (e.g., ACAT1 inhibition) and direct functional restoration of LRP1. While ACAT1 inhibition effectively upregulates LRP1, recent findings suggest that this effect is mechanistically coupled to ADAM10/17-mediated shedding of TREM2. This raises a critical pharmacological dilemma: balancing the benefit of LRP1 upregulation against the reduction of cell-surface TREM2. While TREM2 shedding may represent a functional shift from membrane-bound sensing to soluble Aβ clearance rather than a simple loss of function, cell-surface TREM2 signaling remains essential for Aβ sensing and microglial fitness in the long term. Conversely, strategies focusing on the direct restoration of LRP1 transport achieve robust Aβ clearance but face challenges regarding delivery specificity. Integrating emerging evidence on lipid droplet–driven microglial dysfunction and membrane fluidity, this article discusses the trade-offs of these strategies and proposes that preserving surface TREM2 signaling while enhancing LRP1 activity is key to long-term therapeutic efficacy. Clinical evidence from the INVOKE-2 trial further supports the need for combination strategies targeting both TREM2 signaling and LRP1-mediated clearance.

  • Open Access

    Efficient and specific selection of high-affinity DNA aptamers targeting μ-opioid receptor via functional extracellular vesicles

    by Mitsushi J. Ikemoto, Yuji Kamikubo, Daisuke Uta, Kengo Kirinoki, Mari Kiriyama, Takumi Miyajima, Hakushun Sakairi, Masanobu Kano, Takashi Sakurai, Toshihide Tabata

    Nucleic acid aptamers are promising next-generation experimental and therapeutic drugs for uncharacterized biomolecules and intractable diseases. However, efficient aptamer selection remains challenging. We have developed a functional selection method termed extracellular vesicle (EV)-SELEX that efficiently selects DNA aptamers for G protein-coupled receptors (GPCRs), a major class of drug targets via ligand-dependent GPCR endocytosis and subsequent release of GPCR-containing EVs. Using this method, we obtained Dapt-μR, a DNA aptamer that had a high affinity to μ-opioid receptor (MOR) (Kd ≈ 28 nM) but no other types of opioid receptors. In unmodified form, Dapt-μR acted as a morphine-like, naloxone-sensitive MOR agonist, inhibiting cAMP accumulation in cultured cells and reducing Ca2+ influx in primary striatal neurons. Furthermore, Dapt-μR selectively bound to the MOR-rich spinal cord dorsal horn and produced an analgesic effect following intrathecal administration in mice. These findings demonstrate that EV-SELEX is a powerful method for selecting DNA aptamers for target GPCRs.


  • Open Access

    Silica nanoparticle toxicity: cellular mechanisms, neurotoxicological concerns, and environmental perspectives

    by Yuji Kamikubo, Hakushun Sakairi

    Engineered silica nanoparticles (SiNPs) are increasingly employed in various domains, including biomedicine and industry, owing to their tunable physicochemical properties. However, their extensive application has raised concerns about their potentially detrimental effects on human health and ecosystems. This mini-review summarizes current knowledge of the cellular mechanisms underlying SiNP cytotoxicity, with a focus on oxidative stress, NOD-like receptor protein 3 (NLRP3) inflammasome-mediated inflammation, lysosomal destabilization, mitochondrial dysfunction, genotoxicity, and autophagy modulation. We emphasize the critical influence of SiNP properties such as size, surface chemistry, shape, and synthesis method on these biological responses. Particular attention has been given to neurotoxicity, which is a growing concern owing to the potential of SiNPs to cross the blood-brain barrier. Additionally, we briefly address environmental considerations, recognizing the need to understand the fate and impact of SiNPs within ecosystems. Finally, we discuss mitigation strategies, including surface engineering and safer-by-design approaches, and delineate the key knowledge gaps and future research directions essential for the sustainable development and safe application of SiNP-based technologies in the context of both human health and environmental safety.


  • Open Access

    Efficient Selection of DNA Aptamers with High Affinity and Specificity to GPCRs via Functional Extracellular Vesicles

    by Toshihide Tabata, Mitsushi Ikemoto, Yuji Kamikubo, Daisuke Uta, Kengo Kirinoki, Mari Kiriyama, Takumi Miyajima, Hakushun Sakairi, Masanobu Kano, Takashi Sakurai

    Nucleic acid aptamers are promising new-generation experimental and therapeutic drugs for uncharacterized biomolecules and intractable diseases. However, efficient aptamer selection remains challenging. We present a novel functional selection method termed extracellular vesicle (EV)-SELEX that efficiently selects DNA aptamers for G protein-coupled proteins (GPCRs), a major class of drug targets via ligand-dependent GPCR endocytosis and subsequent release of GPCR-containing EVs. Using this method, we obtained Dapt-μR, a DNA aptamer that had a high affinity to μ-opioid receptor (MOR) (K d ≈ 28 nM) but no other types of opioid receptors. In unmodified form, Dapt-μR acted as a morphine-like, naloxone-sensitive MOR agonist, inhibiting cAMP accumulation in cultured cells and reducing Ca 2+ influx in primary striatal neurons. Furthermore, Dapt-μR selectively bound to the MOR-rich spinal cord dorsal horn and produced an analgesic effect following intrathecal administration in mice. These findings demonstrate that EV-SELEX is a powerful method for selecting DNA aptamers for target GPCRs.

  • Open Access

    Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes

    by Masato Komai, Yuka Noda, Atsuya Ikeda, Nanaka Kaneshiro, Yuji Kamikubo, Takashi Sakurai, Takashi Uehara, Nobumasa Takasugi


  • Open Access

    The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?

    by Nobumasa Takasugi, Masato Komai, Nanaka Kaneshiro, Atsuya Ikeda, Yuji Kamikubo, Takashi Uehara

    Aducanumab, co-developed by Eisai (Japan) and Biogen (U.S.), has received Food and Drug Administration approval for treating Alzheimer’s disease (AD). In addition, its successor antibody, lecanemab, has been approved. These antibodies target the aggregated form of the small peptide, amyloid-β (Aβ), which accumulates in the patient brain. The “amyloid hypothesis” based therapy that places the aggregation and toxicity of Aβ at the center of the etiology is about to be realized. However, the effects of immunotherapy are still limited, suggesting the need to reconsider this hypothesis. Aβ is produced from a type-I transmembrane protein, Aβ precursor protein (APP). One of the APP metabolites, the 99-amino acids C-terminal fragment (C99, also called βCTF), is a direct precursor of Aβ and accumulates in the AD patient’s brain to demonstrate toxicity independent of Aβ. Conventional drug discovery strategies have focused on Aβ toxicity on the “outside” of the neuron, but C99 accumulation might explain the toxicity on the “inside” of the neuron, which was overlooked in the hypothesis. Furthermore, the common region of C99 and Aβ is a promising target for multifunctional AD drugs. This review aimed to outline the nature, metabolism, and impact of C99 on AD pathogenesis and discuss whether it could be a therapeutic target complementing the amyloid hypothesis.


  • Open Access

    Ex vivo analysis platforms for monitoring amyloid precursor protein cleavage

    by Yuji Kamikubo, Hao Jin, Yiyao Zhou, Kazue Niisato, Yoshie Hashimoto, Nobumasa Takasugi, Takashi Sakurai

    Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder and the most common cause of dementia in the elderly. The presence of large numbers of senile plaques, neurofibrillary tangles, and cerebral atrophy is the characteristic feature of AD. Amyloid β peptide (Aβ), derived from the amyloid precursor protein (APP), is the main component of senile plaques. AD has been extensively studied using methods involving cell lines, primary cultures of neural cells, and animal models; however, discrepancies have been observed between these methods. Dissociated cultures lose the brain’s tissue architecture, including neural circuits, glial cells, and extracellular matrix. Experiments with animal models are lengthy and require laborious monitoring of multiple parameters. Therefore, it is necessary to combine these experimental models to understand the pathology of AD. An experimental platform amenable to continuous observation and experimental manipulation is required to analyze long-term neuronal development, plasticity, and progressive neurodegenerative diseases. In the current study, we provide a practical method to slice and cultivate rodent hippocampus to investigate the cleavage of APP and secretion of Aβ in an ex vivo model. Furthermore, we provide basic information on Aβ secretion using slice cultures. Using our optimized method, dozens to hundreds of long-term stable slice cultures can be coordinated simultaneously. Our findings are valuable for analyses of AD mouse models and senile plaque formation culture models.


  • Open Access

    Multifaceted analysis of nanotoxicity using primary cultured neurons

    by Yuji Kamikubo, Tomohito Yamana, Yuriko Inoue, Takashi Sakurai

    Various nanomaterials have been produced with the development of nanotechnology, some of which have been reported to have adverse effects on several types of cells, organs, and the environment. It has been suggested that some small nanoparticles can cross the blood-brain barrier and accumulate in the brain, which may be a potential cause of brain diseases. Neuronal cells are vulnerable to hypoxia, hypotrophy, and mechanical and oxidative stress. Therefore, it is essential to assess the toxicity of nanoparticles to neurons accurately. In this report, we describe a primary culture protocol to evaluate the toxicity of nanoparticles on neurons, a potential high-throughput method for assessing the cytotoxicity, and a method for evaluating the effect on neuronal maturation. This report assessed the toxicity of silicon dioxide, zinc oxide, and iron nanoparticles using rat hippocampal neurons, which are used frequently in pharmacological and physiological studies. Based on the methods and protocols we reported in this report, it may be possible to evaluate nanotoxicity to various neurons by using primary cultures of other brain regions (cerebral cortex, cerebellum, thalamus, etc.), spinal cord, and peripheral nerves.